Olaparib (AZD2281, Ku-0059436)

Catalog No.S1060

Olaparib (AZD2281, Ku-0059436) Chemical Structure

Molecular Weight(MW): 434.46

Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 150 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 83 Publications

18 Customer Reviews

  • CYREN does not regulate repair of replication-induced DSBs. Representative images of chromosomes.

    Nature, 2017, 549(7673):548-552. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Clonogenic survival of cells expressing BARD1(WT)res or BARD1(AAE)res after treatment with olaparib or MMC. Data are means ± s.d., n = 3. EV, empty vector. P values were calculated using two-way ANOVA and multiple comparisons were corrected by the Bonferroni method. ** P < 0.01.

    Nature, 2017, 550(7676):360-365. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • a, IC50 levels of olaparib in EWS–FLI1 mutant cells (n = 17) versus breast cancers (n = 13) or pan-cancer (n = 147) dataset. b, Cell viability of IMR90 and Ewing sarcoma cells with increasing doses of olaparib. Mean ± s.d., n = 3 technical replicates, one-way ANOVA compared to IMR90 cells. c, Cell viability plot demonstrating the role of EWS–FLI1 in mediating exquisite sensitivity to olaparib in U2OS cells transfected with either the oncogene or empty vector; n = 3 transfection replicates.

    Nature, 2018, 555(7696):387-391. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Western blot analysis showing PARylated proteins in cells subject to the indicated PARP inhibitor treatments (5 μM Olaparib and 10 μM NU1025).

    Cell, 2018, 172(3):439-453. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 48 hours, and protein extracts were subjected to western blot analysis with the indicated antibodies.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

     

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 48 hours, and protein extracts were subjected to western blot analysis with the indicated antibodies.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 24 (A) or 12 (B) hours, subjected to staining with propidium iodide (A) or FITC-Annexin V (B), and then analyzed by flow cytometry.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

     

    Mechanism of FK866/olaparib synergy. FK866 exacerbates levels of gH2AX caused by olaparib. CAL51 cells were exposed to FK866 and/or olaparib for 48 h and cell lysates generated and immunoblotted for total and gH2AX.

    EMBO Mol Med 2012 4, 1087-1096. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • Role of PARP and BER in the synergy between PTX and GMX in A549 cells. A) Cells were pre-treated +/- 1 uM olaparib (2h) then sequentially +/- 150nM PTX (24h) then +/- GMX 12nM (48h). Cells were harvested for (left) NAD+ quantification by LC-MS/MS (mean +/-SD of quadruplicates) or (right) viability by CellTiter-Glo (mean +/-SD of duplicates) B) PAR modification of proteins and γ-H2AX levels were measured in extracts treated as in A) by western blotting.

    Cancer Res 2014 74(21), 5948-54. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    J Exp Clin Cancer Res 2013 32(1), 95. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • (A) Representative confocal microscopy images of nuclear γ-H2AX (red) and DAPI (blue) staining in FKO1 cells 30 minutes following irradiation. Cells pre-treated for 24hr with 1μM NanoOlaparib, olaparib, or a vehicle control before irradiation.

    Mol Cancer Ther, 2017, 16(7):1279-1289. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    MSH3-deficient cells are sensitive to olaparib, a PARP inhibitor, and the combination with oxaliplatin. A, clonogenic survival of HCT11635, G5 without doxycycline (DOX), and G5 cells with doxycycline, which were treated with 2 μM of oxaliplatin, 2 μM of olaparib, and the combination of these two drugs. B, clonogenic survival of HT29 cells, which were treated with 1 μM oxaliplatin, 2 μM olaparib, and the combination of these two drugs.

     

     

    J Biol Chem 2011 286, 12157-12165. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • Logarithmic growth curves of human Burkitt lymphoma cells over 5 days with 500 nmol/l of ABT-888 and AZD-2281 in combination with 0 Gy (a), 4 Gy (b), 8 Gy (c), and 12 Gy (d) of external beam radiation. The maximal relative reduction was 65.5% of viable cells and occurred with AZD-2281 (500 nmol/l) on day 5. DMSO, dimethyl sulfoxide.

    Nucl Med Commun 2011 32, 1046-51. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Nucl Med Commun 2011 32, 1046-51. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    Number of foci detected using laser confocal microscopy and fluorescent Fluor 647 anti-H2A.X-phosphorylated (Ser139) antibody. Double-stranded breaks (red) are clearly augmented in cells incubated with 500 nmol/l of ABT-888 and 500 nmol/l of AZD-2281 compared with PBS and 1% dimethyl sulfoxide controls. Image analysis was performed using ImageJ and the ‘analyze particle’ function.

    Nucl Med Commun 2011 32, 1046–1051 . Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Olaparib inhibited cell proliferation, and CRC cells with high XRCC2 expression had higher olaparib sensitivity. The surviving fractions of SW480 cells treated with (A) 1 mM, (B) 10 mM, and (C) 50 mM olaparib were measured using CCK-8. (D) The relation between cell viability and olaparib concentration.

    Medicine (Baltimore) 2014 93(28), e294. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • in vivo suppression of PAR formation by the PARP inhibitor AZD2281 upon induction of DNA damage Primary human lung fibroblast cells (MRC-5) were pre-treated with the indicated concentration of the PARP inhibitor AZD2281 for two hours. Oxidative DNA damage was induced by 500 µM H2O2 for 10 min and cellular PARP activity was measured by immuno-staining of poly(ADP)-ribose (PAR) (right panels). The in vivo effect of PARP inhibition was compared to cells without DNA damage induction and inhibitor (control) and H2O2-treated cells without inhibitor. Average nuclear PAR staining intensities of more than 50 cells were statistically analysed by Kruskal-Wallis and the post-hoc Dunn’s Multiple Comparison tests (left panel). Asterisks indicate highly significant (p<1%) differences to H2O2-treated cells without PARP inhibitor. Thick horizontal bars mark medians and error bars the interquartile range.

    2010 Dr. David Schrmann from University of Base. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Effect of AZD 2281 on the viability of endometrial cancer cell line Hec50 and Ishikawa and ovarian cancer cell line SKOV3,Caov3 and PA-1 was detected by WST-1 method after 3 days treatment.

     

     

    2010 Dr. Xiangbing Meng of University of Iowa. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Description Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1.
Features A potent PARP inhibitor (currently in late stage clinical trials).
Targets
PARP2 [1]
(Cell-free assay)
PARP1 [1]
(Cell-free assay)
1 nM 5 nM
In vitro

Olaparib would act against BRCA1 or BRCA2 mutations. Olaparib is not sensitive to tankyrase-1 (IC50 >1 μM). Olaparib could ablate the PARP-1 activity at concentrations of 30-100 nM in SW620 cells. Olaparib is hypersensitive to BRCA1-deficient cell lines (MDA-MB-463 and HCC1937), compared with BRCA1- and BRCA2-proficient cell lines (Hs578T, MDA-MB-231, and T47D). [1] Olaparib is strongly sensitive to KB2P cells due to suppression of base excision repair by PARP inhibition, which may result in the conversion of single-strand breaks to double-strand breaks during DNA replication, thus activating BRCA2-dependent recombination pathways. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KP3.33 NYjTemc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1W0VVQh\A>? M4LZZ2lEPTB;NT63NFUhKM7:TTC= NWqyc5pvOTh3NUm2NVM>
KP6.3 M4X6ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUK0JIQ> NYTIPVRQUUN3ME2xNE41OjhizszNJC=> NXn6d5FYOTh3NUm2NVM>
KP7.7 M2HjVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXK0JIQ> M1\5W2lEPTB;NUegcm0h M1rNdFE5PTV7NkGz
KB2P3.4 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDjOEBl NXK4UHZ6UUN3ME2xNlQhVSB? NXTpbFZYOTh3NUm2NVM>
KB2P1.21 M1PofWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVK0JIQ> MV;JR|UxRTh7MEegcm0h MkLZNVg2PTl4MUO=
U373-MG MWHDfZRwfG:6aXOgRZN{[Xl? NHzQOHgyKM7:TTC= NFjJ[pozPCCq NHPWT2lKdmO{ZXHz[ZMhemGmaXH0bY9vKHOnboPpeIl3cXS7 M2f3RlE5QTV2N{Gy
T98G NETncFhEgXSxdH;4bYMhSXO|YYm= M3TrWlEh|ryPIB?= MUKyOEBp MX;JcoNz\WG|ZYOgdoFlcWG2aX;uJJNmdnOrdHn2bZR6 NHfEV40yQDl3NEexNi=>
U87-MG MojsR5l1d3SxeHnjJGF{e2G7 MlnsNUDPxE1i NX3GfVV5OjRiaB?= NVP2[FF{UW6lcnXhd4V{KHKjZHnheIlwdiC|ZX7zbZRqfmm2eR?= MVixPFk2PDdzMh?=
UVW Mn\yR5l1d3SxeHnjJGF{e2G7 MYS1NFAhdk1? NIrrOXUzPCCq NX7DR3NwUW6lcnXhd4V{KHKjZHnheIlwdiC|ZX7zbZRqfmm2eR?= M1O2V|E5QTV2N{Gy
HeLa Mly4SpVv[3Srb36gRZN{[Xl? NHW2[Iw2ODBibl2= NFLpd3M1KGh? NUnTXFQ4S2G3c3XzJIEhdW:mZYP0JIRmdGG7IHnuJJJmcm:rbnnu[{Bw\iC{YXTpZZRqd25vaX7keYNm\CCGTlGgZpJm[Wu| NX;o[|JnOTh7NUS3NVI>
HeLa MUfGeY5kfGmxbjDBd5NigQ>? NVH4SWR5OSEQvF2g Mo\DNlQhcA>? MWfFcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDTMZBp[XOnIHHydoV{fA>? NWTVOJg3OTh7NUS3NVI>
T98G M{DSdmZ2dmO2aX;uJGF{e2G7 MlTqNUDPxE1i MUSyOEBp NYDocVE4TW6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQhWy2yaHHz[UBienKnc4S= M3fERVE5QTV2N{Gy
L3 NFHjfmtEgXSxdH;4bYMhSXO|YYm= M4j6S|Uh|ryPIB?= Mnv1PVYhcA>? NFewUWZFVVOR MWLTbYdvcW[rY3HueIx6KGmwaHnibZR{KGOnbHygd5Vzfmm4YXy= MWKyNFEzPDR3OR?=
Granta-519 NFTXS|NEgXSxdH;4bYMhSXO|YYm= NUD6eY9pPSEQvF2g MUm5OkBp NHjQNGNFVVOR Mk\4V4xq\2i2bImgbY5pcWKrdIOgZ4VtdCC|dYL2bZZidA>? M2XKSFIxOTJ2NEW5
BT MlPNR5l1d3SxeHnjJGF{e2G7 MXu1JO69VSB? MVW5OkBp MYXEUXNQ NEXpW5hUdGmpaITsfUBqdmirYnn0d{Bk\WyuIIP1dpZqfmGu NHLQUpMzODF{NES1PS=>
UPN2 NGLMTG5EgXSxdH;4bYMhSXO|YYm= NFjQS4k2KM7:TTC= M4\rflk3KGh? NGW5SGNFVVOR NXjL[FcxW2yrZ3j0cJkhcW6qaXLpeJMh[2WubDDzeZJ3cX[jbB?= MUiyNFEzPDR3OR?=
HBL-2 MX3DfZRwfG:6aXOgRZN{[Xl? NWnzVoJmPSEQvF2g NWLLN25RQTZiaB?= NXeyXGJwTE2VTx?= NUTGPZFbW2yrZ3j0cJkhcW6qaXLpeJMh[2WubDDzeZJ3cX[jbB?= MUWyNFEzPDR3OR?=
JVM-2 MXPDfZRwfG:6aXOgRZN{[Xl? Ml22OUDPxE1i NHvOOpU6PiCq M3fRVWROW09? NE[2dWRUdGmpaITsfUBqdmirYnn0d{Bk\WyuIIP1dpZqfmGu MnjJNlAyOjR2NUm=
Z138 MUHDfZRwfG:6aXOgRZN{[Xl? M3OzVFUh|ryPIB?= M1vpdlk3KGh? MmXHSG1UVw>? NY\xZpZXW2yrZ3j0cJkhcW6qaXLpeJMh[2WubDDzeZJ3cX[jbB?= MX[yNFEzPDR3OR?=
RWPE NIDXTWFKdn[jc3n2[UBCe3OjeR?= NX[2Nmt7OjVizszN NHLU[GI1QCCq M1jzfGROW09? M{DvS3Nq\26rZnnjZY51dHlicnXkeYNmeyCHUlet[JJqfmWwIHPlcIwhcW64YYPpc44> NUOyeZBWOjF3N{W4OlU>
VCaP MVLJcpZie2m4ZTDBd5NigQ>? NWm3dmVVOjVizszN NFjXSW01QCCq MmrtSG1UVw>? NI\1SohUcWewaX\pZ4FvfGy7IILl[JVk\XNiRWLHMYRzcX[nbjDj[YxtKGmwdnHzbY9v M1jq[|IyPTd3OE[1
Mouse H2AX−/− ES Cells NXPLT3NOS3m2b4TvfIlkKEG|c3H5 NX;qXIpPOi53IN88US=> M1jiOVIxKGh? NFrtWFFUcWewaX\pZ4FvfGy7IHnubIljcXS|IHPlcIwhe3W{dnn2ZYw> NH3ScG0zOzN3NUS4PS=>
Mouse ATM−/− ES Cells NGjZRmJEgXSxdH;4bYMhSXO|YYm= MUCyMlUh|ryP NXLhNodjOjBiaB?= MkKzV4lodmmoaXPhcpRtgSCrbnjpZol1eyClZXzsJJN2en[rdnHs NUS0TVdEOjN|NUW0PFk>
H1650 NYnlRldPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3zNGY{OjBizszN NGrBcHgyPDRiaB?= M1vzcmlEPTB;MUWuOFch|ryP NInOZ40zOzJ|OUiwPS=>
H1650PTEN+ NFn1TFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rUZ|IxKM7:TR?= NHvIPWUyPDRiaB?= M3TlTGlEPTB;NUCuPFMh|ryP MVOyN|I{QThyOR?=
PC-9 NGnZfFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfzNlAh|ryP M4T6TFE1PCCq MlnXTWM2OD13Lki4JO69VQ>? NUHwUGhvOjN{M{m4NFk>
PC-9PTEN− NXjG[GltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV6yNEDPxE1? M{\ub|E1PCCq NGHNd2JKSzVyPU[uOVIh|ryP MWCyN|I{QThyOR?=
MDA-MB-231 M1GyOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PuOlUh\GG7 M2mzVGlEPTB;Nj65JO69VQ>? Ml7LNlM4PjB2OU[=
MDA-MB-468 Mm\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXQeIo5PSCmYYm= NYDRVI45UUN3ME21MlAh|ryP NIjNWm8zOzd4MES5Oi=>
BT20 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;3ZVRkPSCmYYm= NWTXToFQUUN3ME23Mlch|ryP M1jRPVI{PzZyNEm2
HCC1143 Mm\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUi1JIRigQ>? NIDJZYpKSzVyPUGxMlEh|ryP MX:yN|c3ODR7Nh?=
HCC1937 MmH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nnTlUh\GG7 MkexTWM2OD1zMj62JO69VQ>? MmH6NlM4PjB2OU[=
Hs578t Mlr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVe1JIRigQ>? M1\pb2lEPTB;NT62JO69VQ>? NUTRfGUzOjN5NkC0PVY>
Hs578t(si) MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUe0Oox1PSCmYYm= MXjJR|UxRTdwNTFOwG0> M3rG[VI{PzZyNEm2
BT474 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jKTVUh\GG7 NVHxZ|BDUUN3ME2xPU45KM7:TR?= NIHC[GwzOzd4MES5Oi=>
JIMT1 NVXYV2NiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXq1JIRigQ>? MUPJR|UxRTdwNzFOwG0> M{K0d|I{PzZyNEm2
SKBR3 NV\lSXg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHq5Tno2KGSjeR?= NVGxTGo4UUN3ME2xNU4yKM7:TR?= NUnrO2hDOjN5NkC0PVY>
SUM159 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVn3[5ZXPSCmYYm= MlvLTWM2OD12LkKg{txO NHzXdlAzOzd4MES5Oi=>
CAMA1 NULtZlNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHjS2JTPSCmYYm= MWrJR|UxRTF3Lkig{txO MnXINlM4PjB2OU[=
MCF7 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnOOYs2KGSjeR?= NHXaRZFKSzVyPUWuPEDPxE1? NEO4fpIzOzd4MES5Oi=>
T47D MnTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEH1Now2KGSjeR?= M1LpSWlEPTB;OT62JO69VQ>? NFjJdJYzOzd4MES5Oi=>
HCT116 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX:xNFAh|ryP M33BSFQ5KGh? NFz4boZFVVOR MVrJR|UxRTJwNTFOwG0h NUXqVYxtOjR3N{e5OFE>
SW1116 NYjRN4VwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3JfIVIOTByIN88US=> NVH0fVFQPDhiaB?= MXnEUXNQ M4\zS2lEPTB;MUCwJO69VQ>? NUK5N2RIOjR3N{e5OFE>
HT29 NUHZ[Y5PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYCxNFAh|ryP NIXjR4s1QCCq NGXGSZlFVVOR MmKxTWM2OD1zND63JO69VQ>? M1jMcFI1PTd5OUSx
LoVo MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofSNVAxKM7:TR?= MXu0PEBp NYj3VIZ3TE2VTx?= MmLGTWM2OD1zMz60JO69VQ>? M320elI1PTd5OUSx
HCT-15 M{jPTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\4clExOCEQvF2= MX[0PEBp MWDEUXNQ M2THb2lEPTB;MUCg{txO M162d|I1PTd5OUSx
SW48 MkLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml2zNVAxKM7:TR?= NFTN[2o1QCCq M2fSdWROW09? NUTNfY1EUUN3ME25MlUh|ryP NUjESHFjOjR3N{e5OFE>
C-1 NVfYU|FET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3GVo5kOTByIN88US=> MmDzOFghcA>? Mo\ISG1UVw>? NUPzO5RpUUN3ME23MlYh|ryP M3LmWFI1PTd5OUSx
RKO M4\iT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWCxNFAh|ryP M4jPTFQ5KGh? MlfZSG1UVw>? MXvJR|UxRTVwOTFOwG0> MXKyOFU4Pzl2MR?=
HCT116 MojuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlGzNVAxKM7:TR?= MkHCOFghcA>? M4rGWGROW09? NF3RTm9Rd3SnboTpZZRmeyCVTj2zPEBkgXSxdH;4bYNqfHli NX\oWYNGOjR3N{e5OFE>
SW1116 MoT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfpNVAxKM7:TR?= NUTtdWg4PDhiaB?= MkTrSG1UVw>? NEjBc3NRd3SnboTpZZRmeyCVTj2zPEBkgXSxdH;4bYNqfHli NUfSWIRqOjR3N{e5OFE>
HT29 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DkTVExOCEQvF2= MlvvOFghcA>? NVzRepg3TE2VTx?= M4fsO3BwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB? MVWyOFU4Pzl2MR?=
LoVo NXj5NZN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPDNVAxKM7:TR?= MmXlOFghcA>? NXjaRnZUTE2VTx?= NH\zPJlRd3SnboTpZZRmeyCVTj2zPEBkgXSxdH;4bYNqfHli NVq2ZoRzOjR3N{e5OFE>
SW48 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUixNFAh|ryP M4HvblQ5KGh? MV\EUXNQ MVHQc5RmdnSrYYTld{BUVi1|ODDjfZRwfG:6aXPpeJkh NELwc2wzPDV5N{m0NS=>
C-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jCZVExOCEQvF2= NYHZVIdTPDhiaB?= MmjTSG1UVw>? M1\id3BwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB? NY\GeFM2OjR3N{e5OFE>
RKO NVHiU2ZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULDfYlLOTByIN88US=> NX7keIo{PDhiaB?= Mnq2SG1UVw>? MVvQc5RmdnSrYYTld{BUVi1|ODDjfZRwfG:6aXPpeJkh M{XsS|I1PTd5OUSx
HCT116 M3\oVWZ2dmO2aX;uJGF{e2G7 MWKxNEBvVQ>? MoLlNVIhcA>? MXfEUXNQ MY\JcoNz\WG|ZYOgSG5CKGSxdXLs[U1{fHKjbnSgZpJm[Wu|IHnu[JVk\WRiYomgV24uOzh? MYqyOFU4Pzl2MR?=
HT29 MX3GeY5kfGmxbjDBd5NigQ>? NIXhZYUyOCCwTR?= M2r6[|EzKGh? NYDVbXpFTE2VTx?= MWDJcoNz\WG|ZYOgSG5CKGSxdXLs[U1{fHKjbnSgZpJm[Wu|IHnu[JVk\WRiYomgV24uOzh? M3jSblI1PTd5OUSx
TE-6 M4X5dWZ2dmO2aX;uJGF{e2G7 MUK1JO69VSB? NEf4W5cyOiCq MWnEUXNQ M3;IcWlv\HWlZYOgS|IwVSCjcoLld5Q> NGfVeGYzPDJzOUG2OC=>
TE-6 NVfaWIVxTnWwY4Tpc44hSXO|YYm= NH\FbVI2KM7:TTC= MlS5NlQhcA>? NF6zd4xFVVOR NFKyPFZKdmO{ZXHz[ZMhcW5iZH;1ZoxmKHO2cnHu[EBjemWja4OgLGRUSnNr MXWyOFIyQTF4NB?=
Hep3B NHPOOGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWS0NEDPxE1i NVPK[o1FPzJiaB?= NWrSUIVLTE2VTx?= M{XKRXN6dmW{Z3nzeIlk[WyueTDpcohq[mm2czDj[YxtKGe{b4f0bEB4cXSqIFTIUWVS Ml;ONlUxPzJ5NUK=
Huh7 NET0NoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PvOFQxKM7:TTC= NXL3O4FiPzJiaB?= Mn3LSG1UVw>? NH2zV3hUgW6ncnfpd5Rq[2GubImgbY5pcWKrdIOgZ4VtdCCpcn;3eIghf2m2aDDETG1GWQ>? M4nFUlI2ODd{N{Wy
Hep3B MlvOSpVv[3Srb36gRZN{[Xl? NUHRd3FnPDBizszNJC=> MmPXNlQhcA>? NGrCd5ZFVVOR NFzYSFNKdmS3Y3XzJHJQWyCycn;keYN1cW:wIIfpeIghTEiPRWG= MXOyOVA4Ojd3Mh?=
Huh7 NUDQ[ldxTnWwY4Tpc44hSXO|YYm= NVnvN2N1PDBizszNJC=> Ml3NNlQhcA>? NUGxS2d7TE2VTx?= MUTJcoR2[2W|IGLPV{Bxem:mdXP0bY9vKHerdHigSGhOTVF? NU\IfW9sOjVyN{K3OVI>
Hep3B NIexT5lHfW6ldHnvckBCe3OjeR?= MoDkOFAh|ryPIB?= MonGNlQhcA>? MVzEUXNQ NVXMUXQ2UW6mdXPld{Bk\WyuIHH1eI9xcGGpeTD3bZRpKESKTVXR M{LUOVI2ODd{N{Wy
Huh7 M4e1[mZ2dmO2aX;uJGF{e2G7 NHPoXmM1OCEQvF2g MV2yOEBp MnjQSG1UVw>? M{f6dWlv\HWlZYOgZ4VtdCCjdYTvdIhi\3lid3n0bEBFUE2HUR?= NWrIb5dnOjVyN{K3OVI>
SGC-7901 Ml3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVqzNOKh|ryP M2TseVQ5KGh? NXzmdpoxTE2VTx?= MX\CcI9kcyCxeHHsbZBt[XSrbj3pcoR2[2WmIHPlcIwh\GWjdHi= NG\vUWEzPTd4N{C3Oi=>
COLO-800 Ml62S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvWTWM2OD1yLkS0NVY1KM7:TR?= NInPe4NUSU6JRWK=
EoL-1- M2LRfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;CdmRKSzVyPUCuOVY1PDZizszN M1\jS3NCVkeHUh?=
NCI-H209 M4jJfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTBwOUG1OVYh|ryP MWnTRW5ITVJ?
ES1 NETQWnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPlTWM2OD1zLkGxOFA5KM7:TR?= MnrQV2FPT0WU
NKM-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DUVGlEPTB;MT6yOVM1PyEQvF2= M1fK[XNCVkeHUh?=
NTERA-S-cl-D1 Moq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HTOmlEPTB;MT6zN|M1OSEQvF2= MnPiV2FPT0WU
MHH-ES-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrLe3V6UUN3ME2xMlYzODZ5IN88US=> MXHTRW5ITVJ?
ES8 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\TTWM2OD1zLkeyOFE1KM7:TR?= M174SHNCVkeHUh?=
NCI-H720 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTJwMkC2PVkh|ryP MnHTV2FPT0WU
EW-3 MnHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml61TWM2OD1{LkK3OVM1KM7:TR?= MlezV2FPT0WU
D-566MG MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHGVFBKSzVyPUKuOFQ2PjhizszN NYTZbYJyW0GQR1XS
697 NF64bY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXabIZ5UUN3ME2yMlg1OTd|IN88US=> M4\ze3NCVkeHUh?=
ES5 MkWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTJwOEixPFkh|ryP NVrCUXZDW0GQR1XS
COLO-684 M1nhcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHCTWM2OD1|LkWxOlk3KM7:TR?= MkS3V2FPT0WU
ML-2 M{XqV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfDOJVKSzVyPUOuOlAxPThizszN M3vNTnNCVkeHUh?=
MC-IXC MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDITWM2OD1|Lk[zN|k{KM7:TR?= NEG0bG9USU6JRWK=
DB MkP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTNwNkW0OFgh|ryP Ml3zV2FPT0WU
HCC2218 M1jM[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvaVoRKSzVyPUOuO|MyODNizszN NHfQVolUSU6JRWK=
NCI-H510A M{S2d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXP6PG13UUN3ME2zMlgzPzJ2IN88US=> NHjq[odUSU6JRWK=
NCI-H526 Ml\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXVTWM2OD1|Lki2PVU5KM7:TR?= M4j5OXNCVkeHUh?=
MV-4-11 M17tdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjkXlhQUUN3ME20MlE{OzN2IN88US=> MmLKV2FPT0WU
PA-1 M{fxUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE[2VIpKSzVyPUSuNlUzQSEQvF2= MVHTRW5ITVJ?
EW-22 NV;BNolWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrhZ5RKSzVyPUSuN|U5PiEQvF2= MYfTRW5ITVJ?
KASUMI-1 MmnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXsc4lKSzVyPUSuOFAyODlizszN MlzjV2FPT0WU
LU-139 NIPsPHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljMTWM2OD12Lke1PFI6KM7:TR?= NFfVXIZUSU6JRWK=
SBC-1 M{PLOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrnZVZKSzVyPUSuPFA6ODhizszN M{Pae3NCVkeHUh?=
H4 M17wNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTUNnRKSzVyPUSuPFk1PDNizszN MnLFV2FPT0WU
EW-11 NF3JPYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLYbWpKSzVyPUWuNFgxPzJizszN NH\KVFJUSU6JRWK=
NBsusSR NYf1RmEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnj2TWM2OD13LkGyNFU2KM7:TR?= MnviV2FPT0WU
RPMI-8226 M3jDS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTVwMUWyOFQh|ryP Mk\6V2FPT0WU
DEL NUjhR5dIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHf1cFBKSzVyPUWuNlAxODZizszN MV3TRW5ITVJ?
ES4 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPSTWM2OD13LkWxN|g6KM7:TR?= M4rSdnNCVkeHUh?=
GCT M3mxfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXhTmJKSzVyPUWuOVY5PTZizszN MlHoV2FPT0WU
NCI-H1048 NEnGcohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTVwOUeyO|Mh|ryP NIXwOGRUSU6JRWK=
NCI-SNU-1 Mn:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPYOnpNUUN3ME22MlAzOiEQvF2= MmjHV2FPT0WU
ES7 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrIO4pKSzVyPU[uNFM2PzdizszN NI[zfndUSU6JRWK=
SW982 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofwTWM2OD14LkC5NVM4KM7:TR?= MVjTRW5ITVJ?
L-363 NX7EXo84T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnu1TWM2OD14LkOzPVc1KM7:TR?= NEHQUY5USU6JRWK=
HT-1080 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTZwNEm2PFMh|ryP NVXrd4RoW0GQR1XS
HAL-01 M4DzZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvuTWM2OD14LkWxNFkh|ryP NHTXWIJUSU6JRWK=
NB14 NHLNbmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MornTWM2OD14Lk[0NFM6KM7:TR?= M1n3eHNCVkeHUh?=
EW-13 MkD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLWTWM2OD14Lke3OFI1KM7:TR?= M2X4N3NCVkeHUh?=
NY NGHlNmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TpWmlEPTB;Nj65OFYxPSEQvF2= MkG2V2FPT0WU
NCI-SNU-5 NUS5R4JxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTdwMUC0N|Mh|ryP MWLTRW5ITVJ?
MS-1 Mme5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\pSVhKSzVyPUeuNVc1QTRizszN MYTTRW5ITVJ?
EW-16 MnvBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTdwM{G4OlEh|ryP NWLldmFtW0GQR1XS
LU-65 NEH5bJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPObHZKSzVyPUeuOFg1OTdizszN NVXud|k4W0GQR1XS
HGC-27 NXm5cYQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2K4XmlEPTB;Nz63NlE4OyEQvF2= NF;qRmRUSU6JRWK=
CTB-1 NYfFT|gzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHUTHJJUUN3ME23Mlc3OTd3IN88US=> MYHTRW5ITVJ?
5637 NUjjV2RUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTPfodCUUN3ME23MlkzQDZizszN M1HqTHNCVkeHUh?=
U251 MoDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{C4eWlEPTB;Nz65OFAyPiEQvF2= NYC1OW5ZW0GQR1XS
HOS MlW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXQeGxKSzVyPUiuNlMxODdizszN NYL4d5BqW0GQR1XS
DOHH-2 M37BdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fOXWlEPTB;OD6yN|U5KM7:TR?= NF7weZBUSU6JRWK=
EW-1 NIfCco1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRThwM{CwPFgh|ryP MWDTRW5ITVJ?
BV-173 NUfzcJp[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIX3dJdKSzVyPUiuOVU2PCEQvF2= M1;D[3NCVkeHUh?=
8-MG-BA MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHO4Z3NKSzVyPUiuOlg6QDhizszN M2D2OHNCVkeHUh?=
NB69 M4j1SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XWXWlEPTB;OD63NFkzOSEQvF2= MkDkV2FPT0WU
NCI-H69 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYThV4pKUUN3ME25MlkxQTZzIN88US=> MXnTRW5ITVJ?
RS4-11 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjDTlVKUUN3ME2xNU4zOjB6IN88US=> M2KwcXNCVkeHUh?=
ONS-76 NEXEZYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXOdJVKSzVyPUGxMlI6PDdizszN M4r1cHNCVkeHUh?=
SF539 NV\nUoNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moi2TWM2OD1zMT60PFg6KM7:TR?= MlrPV2FPT0WU
HuO-3N1 M1LIW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTL[mdKSzVyPUGxMlU4QTZizszN MYHTRW5ITVJ?
NCI-H1651 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXwW25KSzVyPUGyMlMyOTVizszN MnfrV2FPT0WU
KARPAS-45 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXTTWM2OD1zMj6zO|Yh|ryP M1zifXNCVkeHUh?=
SK-NEP-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\PbmpnUUN3ME2xNk41PjB7IN88US=> NXrsfGptW0GQR1XS
LAMA-84 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jQc2lEPTB;MUOuNVA6PSEQvF2= M1\1e3NCVkeHUh?=
NCI-H1155 Mki1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTVSJNKSzVyPUGzMlI5PTZizszN MlTmV2FPT0WU
CTV-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDpPI52UUN3ME2xN{41PDVizszN M3rlR3NCVkeHUh?=
QIMR-WIL Mk[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jadGlEPTB;MUOuO|gyPCEQvF2= MoC3V2FPT0WU
H9 M4HuXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTF|Lki0O|Uh|ryP NHHWVYtUSU6JRWK=
SK-MEL-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYX6UXkyUUN3ME2xN{46OzR5IN88US=> MYTTRW5ITVJ?
HD-MY-Z M1vIemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XXRmlEPTB;MUSuNFY{PyEQvF2= NUTOSINvW0GQR1XS
TI-73 NY[2RlVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1SzPWlEPTB;MUSuNlM2PiEQvF2= Mm\rV2FPT0WU
JVM-3 M{DsPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDyTWM2OD1zNT61O|E3KM7:TR?= NIS0clVUSU6JRWK=
D-247MG MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLIVXlKSzVyPUG1MlU6OyEQvF2= Mlf2V2FPT0WU
VA-ES-BJ NGjMdZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUL4UYNsUUN3ME2xOU43ODl5IN88US=> MnnFV2FPT0WU
NOS-1 MlfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHUUnVoUUN3ME2xOU43PTJ{IN88US=> NWe4dI5[W0GQR1XS
MOLT-4 MoTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLqWnZKSzVyPUG2Mlc2OiEQvF2= NILKU3lUSU6JRWK=
Mo-T NHTR[XRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrrTWM2OD1zNz6wPFQ6KM7:TR?= MWDTRW5ITVJ?
NCI-H1770 Mlf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;HU2FzUUN3ME2xO{4yPTR|IN88US=> NET2NWlUSU6JRWK=
COLO-320-HSR MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnPfm5wUUN3ME2xO{4yQDJ5IN88US=> NVLyeoxLW0GQR1XS
TE-12 NXWyZ5o{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHHTWM2OD1zNz63NFU1KM7:TR?= MkD5V2FPT0WU
NCI-H82 M1LXOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTIVGdKSzVyPUG3Mlg4OjhizszN MUTTRW5ITVJ?
NEC8 M1vBdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nwXGlEPTB;MUiuNVMyPiEQvF2= NVm4UY5lW0GQR1XS
HSC-3 NHvu[3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PUSGlEPTB;MUiuO|QyPCEQvF2= NULRbmRPW0GQR1XS
NCI-H1092 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTtTWM2OD1zOD63OVk2KM7:TR?= MkOyV2FPT0WU
NCI-H292 M4Lhcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTF7LkC0PFkh|ryP MkfYV2FPT0WU
L-428 NIPzTFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13BU2lEPTB;MUmuOVU6KM7:TR?= MWTTRW5ITVJ?
LU-134-A MnSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nOfGlEPTB;MUmuOVczKM7:TR?= MknSV2FPT0WU
GI-ME-N M4ri[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPvZWRyUUN3ME2xPU42PzR5IN88US=> MmHLV2FPT0WU
ALL-PO NF;VUIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7nRWpXUUN3ME2xPU42QTd{IN88US=> M1PmSXNCVkeHUh?=
D-283MED MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;GPVdKSzVyPUG5MlkyPSEQvF2= MYDTRW5ITVJ?
D-423MG M{XFUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXSTWM2OD1zOT65PVY4KM7:TR?= NV[3eGhTW0GQR1XS
CAKI-1 MkPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1riTGlEPTB;MkCuNlIyQSEQvF2= M2jROnNCVkeHUh?=
ETK-1 NEO3NWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInYd4NKSzVyPUKwMlI3OTVizszN M2fhR3NCVkeHUh?=
G-402 NEWxXHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\MTWM2OD1{MD61N|M1KM7:TR?= MYXTRW5ITVJ?
HL-60 Ml3FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTJzLkG2NVMh|ryP NF;TTYhUSU6JRWK=
A2058 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DIc2lEPTB;MkGuOFQ4PyEQvF2= NEGzco9USU6JRWK=
CHP-212 NF2zdFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1r4SWlEPTB;MkGuPVA2OSEQvF2= M{T0THNCVkeHUh?=
KY821 NETIfmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7FTWM2OD1{MT65O|Uh|ryP MUHTRW5ITVJ?
TYK-nu MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzURllKSzVyPUKyMlA3PTFizszN NVTEOYNxW0GQR1XS
JVM-2 NX74fJo4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInUPI5KSzVyPUKyMlI6QDNizszN MUDTRW5ITVJ?
KU812 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvuNY9KSzVyPUKyMlc{OTJizszN M37McXNCVkeHUh?=
MKN28 M3HiUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTJ{LkmwNVUh|ryP MYnTRW5ITVJ?
ECC10 M4T0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3uz[WlEPTB;MkOuO|QyKM7:TR?= M2DmNHNCVkeHUh?=
BHT-101 NXnw[YlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkX5TWM2OD1{ND6wNFA5KM7:TR?= Mm\DV2FPT0WU
DU-4475 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HmS2lEPTB;MkSuN|M{PyEQvF2= MX;TRW5ITVJ?
769-P NIqwPJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLRS5dKSzVyPUK0Mlg1PjZizszN MV7TRW5ITVJ?
HEC-1 M2DXcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrmdI92UUN3ME2yOU41PDVizszN NHTTS|ZUSU6JRWK=
MOLT-13 M3PPUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmriTWM2OD1{NT61N|MyKM7:TR?= MV3TRW5ITVJ?
8505C NH3OUIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTJ4LkS5O|ch|ryP Mnu2V2FPT0WU
GB-1 M2HX[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXQc5ZKSzVyPUK2MlcyPzZizszN M4myVHNCVkeHUh?=
SF126 NXPCeIdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fxUWlEPTB;Mk[uO|Y1QCEQvF2= MVPTRW5ITVJ?
A4-Fuk NGLGOXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHnfVJKSzVyPUK3MlEzPzFizszN MUnTRW5ITVJ?
OVCAR-8 MkfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLNW3dKSzVyPUK3MlE2OzlizszN MXXTRW5ITVJ?
NCI-H1304 NWK2cWNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGT6elhKSzVyPUK3MlU1KM7:TR?= NF;RZXhUSU6JRWK=
GR-ST MliwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTJ6LkC0O{DPxE1? Ml\EV2FPT0WU
G-401 M{\CXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTJ6LkWwPVYh|ryP NV3lfJpOW0GQR1XS
LXF-289 M1rabGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTJ6LkW2OVEh|ryP MYnTRW5ITVJ?
DBTRG-05MG NH\KOHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTZTWM2OD1{OD65NlA1KM7:TR?= M1j3bnNCVkeHUh?=
YKG-1 M{HXZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jPR2lEPTB;MkmuPFY5KM7:TR?= Mki4V2FPT0WU
GAMG Mn;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPPTWM2OD1{OT65PVMh|ryP NX;OOodYW0GQR1XS
HCT-116 M13zRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTPOYtFUUN3ME2zNE4xPTR6IN88US=> MVHTRW5ITVJ?
S-117 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LBN2lEPTB;M{GuNlI2PyEQvF2= M4jCcXNCVkeHUh?=
NCI-H1693 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHj1b21KSzVyPUOzMlY2PDJizszN MmLwV2FPT0WU
A427 NIjX[mJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXv2XWVMUUN3ME2zN{46QTd4IN88US=> M4fRPHNCVkeHUh?=
HT-29 MlfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfvTWM2OD1|ND62NFMzKM7:TR?= NV75[ItmW0GQR1XS
P12-ICHIKAWA NFTWS|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTN2Lke0PVEh|ryP M33ZV3NCVkeHUh?=
CAL-51 MlPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;B[3RGUUN3ME2zOU4xPzB7IN88US=> MnvvV2FPT0WU
Ramos-2G6-4C10 NUDNZVNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrPWXBKSzVyPUO1MlI1OjVizszN MXnTRW5ITVJ?
SCH NInaO3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDze2s1UUN3ME2zOk41OTd2IN88US=> NUTxdVk4W0GQR1XS
SK-MEL-24 MofMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPlTWM2OD1|Nj65NFQ1KM7:TR?= NIjBS4JUSU6JRWK=
SW1573 M3PDcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTN6LkeyNVYh|ryP NV6wc4JqW0GQR1XS
BALL-1 M4frSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnRdIxKSzVyPUO5MlIyOjlizszN MYXTRW5ITVJ?
BE-13 MlvUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nC[GlEPTB;M{muN|I6KM7:TR?= NIHmVmNUSU6JRWK=
GI-1 M13qTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHVTWM2OD1|OT64OlQ4KM7:TR?= NF;jTG9USU6JRWK=
GOTO Ml\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGX5eWFKSzVyPUO5MlkyOzlizszN NVXuWmd3W0GQR1XS
A673 NFHKXGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7UPXY2UUN3ME20NU4xOzR|IN88US=> MmLaV2FPT0WU
KG-1 M4fCWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoqzTWM2OD12Mz6zPVQh|ryP MWLTRW5ITVJ?
GP5d M1rYTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDSTWM2OD12ND6wOlY3KM7:TR?= MXXTRW5ITVJ?
MFM-223 NFPsWVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWK1RnZwUUN3ME20OE4yOjJ6IN88US=> MlfZV2FPT0WU
OAW-42 NUHJXWs{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{O3VGlEPTB;NESuNlY1OyEQvF2= MUjTRW5ITVJ?
C8166 M{fzXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlriTWM2OD12NT6wPFIzKM7:TR?= Mn\qV2FPT0WU
LU-99A M1Lxb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF[wdphKSzVyPUS2MlE{OjJizszN NG[2dVVUSU6JRWK=
NCI-H23 M4DnV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYq4cJFwUUN3ME20Ok4yPzh3IN88US=> Ml6xV2FPT0WU
HO-1-N-1 NHToV2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Sw[GlEPTB;NEeuNFk6QCEQvF2= MV7TRW5ITVJ?
A3-KAW Mn7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjMUGt5UUN3ME20O{4yODB5IN88US=> MVnTRW5ITVJ?
CGTH-W-1 M{\yemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPaTWM2OD12Nz61NFY6KM7:TR?= MUXTRW5ITVJ?
DJM-1 MnnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTYTWM2OD12Nz61OFE{KM7:TR?= M2\zUXNCVkeHUh?=
A101D M3ntbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LYPWlEPTB;NEeuOlM2PyEQvF2= NHjVS49USU6JRWK=
BB30-HNC NIGzbW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTR6LkOwO|Ih|ryP MknuV2FPT0WU
T98G MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfiTpFKSzVyPUS4MlQ3OzNizszN MmHRV2FPT0WU
NCI-H1573 NHrnOHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTR7LkS0OlIh|ryP MVnTRW5ITVJ?
MEG-01 MlLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3zTWM2OD12OT63OFEyKM7:TR?= MWDTRW5ITVJ?
WM-115 NEC3fI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXr[GtKSzVyPUS5MlkzOjJizszN NXLyfpdjW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Combining with temozolomide, Olaparib (10 mg/kg, p.o.) significantly suppresses tumor growth in SW620 xenografts. [1] Olaparib shows great response to Brca1-/-;p53-/- mammary tumors (50 mg/kg i.p. per day), while no responses to HR-deficient Ecad-/-;p53-/- mammary tumors. Olaparib even does not show dose-limiting toxicity in tumor-bearing mice. [3] Olaparib has been used to treat with BRCA mutated tumors, such as ovarian, breast and prostate cancers. Moreover, Olaparib shows selectively inhibition to ATM (Ataxia Telangiectasia Mutated)-deficient tumor cells, which indicates to be a potential agent for treating ATM mutant lymphoid tumors. [4]

Protocol

Kinase Assay:

[1]

+ Expand

FlashPlate assay (96-well screening assay):

To columns 1 through 10, 1 μL of Olaparib (in DMSO) is added, and 1 μL DMSO only is added to the positive (POS) and negative (NEG) control wells (columns 11 and 12, respectively) of a pretreated FlashPlate. PARP-1 is diluted 1:40 in buffer (buffer B: 10% glycerol (v/v), 25 mM HEPES, 12.5 mM MgCl2,50 mM KCl, 1 mM DTT, 0.01% NP-40 (v/v), pH 7.6) and 40 μL added to all 96 wells (final PARP-1 concentration in the assay is ~1 ng/μL). The plate is sealed and shaken at RT for 15 min. Following this, 10 μL of positive reaction mix (0.2 ng/μL of double-stranded oligonucleotide [M3/M4] DNA per well, 5 μM of NAD+ final assay concentration, and 0.075 μCi 3H-NAD+ per well) is added to the appropriate wells (columns 1-11). The negative reaction mix, lacking the DNA oligonucleotide, is added to column 12 (with the mean negative control value used as the background). The plate is resealed and shaken for a further 60 min at RT to allow the reaction to continue. Then, 50 μL of ice-cold acetic acid (30%) is added to each well to stop the reaction, and the plate is sealed and shaken for a further 60 min at RT. Tritiated signal bound to the FlashPlate is then determined in counts per minute (CPM) using the TopCount plate reader.
Cell Research:

[1]

+ Expand
  • Cell lines: Breast cancer cell lines including SW620 colon, A2780 ovarian, HCC1937, Hs578T, MDA-MB-231, MDA-MB-436, and T47D
  • Concentrations: 1-300 nM
  • Incubation Time: 7-14 days
  • Method:

    The cytotoxicity of Olaparib is measured by clonogenic assay. Olaparib is dissolved in DMSO and diluted by culture media before use. The cells are seeded in six well plates and left to attach overnight. Then Olaparib is added at various concentrations and the cells are incubated for 7-14 days. After that the surviving colonies are counted for calculating the IC50.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: Brca1-/-;p53-/- mammary tumors are generated in K14cre;Brca1F/F;p53F/F mice.
  • Formulation: 50 mg/mL stocks in DMSO with 10% 2-hydroxyl-propyl-β-cyclodextrine/PBS
  • Dosages: 50 mg/kg
  • Administration: Administered via i.p. injection at 10 μL/g of body weight
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 86 mg/mL warmed (197.94 mM)
Water 0.002 mg/mL (0.0 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 434.46
Formula

C24H23FN4O3

CAS No. 763113-22-0
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03462342 Recruiting High Grade Serous Carcinoma University of Pennsylvania|AstraZeneca March 9 2018 Phase 2
NCT03117933 Recruiting Ovarian Cancer University of Oxford|AstraZeneca March 9 2017 Phase 2
NCT03106987 Recruiting Epithelial Ovarian Cancer AstraZeneca|European Network of Gynaecological Oncological Trial Groups (ENGOT) June 8 2017 Phase 3
NCT02484404 Recruiting Lung Cancer|Breast Cancer|Ovarian Cancer|Colorectal Cancer|Prostate Cancer|Triple Negative Breast Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) June 8 2015 Phase 1|Phase 2
NCT00679783 Active not recruiting Ovarian Carcinoma|Breast Cancer AstraZeneca|British Columbia Cancer Agency July 8 2008 Phase 2
NCT03008278 Recruiting Gastroesophageal Junction Adenocarcinoma|Recurrent Gastric Carcinoma|Stage IV Gastric Cancer AJCC v7 National Cancer Institute (NCI) November 7 2017 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I saw that the solubility of the compound for in vivo on the website had been changed, why the change has been made?

  • Answer:

    For the formulation for in vivo, the compound dissolving in 15% Captisol (former solubility) is a suspension, and it is fine for oral gavage. And now, dissolving in 4% DMSO+30% PEG 300+ddH2O is a clear solution, and is for injection.

  • Question 2:

    How long can the chemical compound be stable in DMEM at 4 °C?

  • Answer:

    The compound is stable in DMEM at 4 degree for one week.

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products

Tags: buy Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) supplier | purchase Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) cost | Olaparib (AZD2281, Ku-0059436) manufacturer | order Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID